Vaccines for Moraxella catarrhalis and non-typeable Haemophilus influenzae

Current Opinion in Investigational Drugs

Volumn 4, Issue 8, 2003, Pages 953-958

  McMichael, John C ^a   Green, Bruce A ^a  

^a PFIZER INC   (United States)

Author keywords

Animal model; Chronic obstructive pulmonary disease (COPD); Complement dependent bactericidal activity; Otitis media; Vaccine antigens

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CATARRHALIS OUTER MEMBRANE PROTEIN B; CATARRHALIS OUTER MEMBRANE PROTEIN E; EPITOPE; HEMAGGLUTININ; HIGH TEMPERATURE REQUIREMENT PROTEASE A; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G3; INTEGRAL OUTER MEMBRANE PROTEIN; LIPOOLIGOSACCHARIDE; LIPOOLIGOSACCHARIDE PROTEIN CONJUGATE; LIPOPROTEIN D; MORAXELLA CATARRHALIS VACCINE; OUTER MEMBRANE ASSOCIATED PROTEIN; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN 26; OUTER MEMBRANE PROTEIN D; OUTER MEMBRANE PROTEIN P4; OUTER MEMBRANE PROTEIN P5; OUTER MEMBRANE PROTEIN P6; PROTEIN OPAA; PROTEIN OPAB; RECOMBINANT 5' NUCLEOTIDASE ACTIVITY PROTEIN; TRANSFERRIN BINDING PROTEIN B; UBIQUITOUS SURFACE PROTEIN A1; UBIQUITOUS SURFACE PROTEIN A2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; MORAXELLA CATARRHALIS; NONHUMAN; OTITIS MEDIA; REVIEW;

ANIMALS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; MORAXELLA (BRANHAMELLA) CATARRHALIS;

EID: 0141496285     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Teele DW, Klein JO, Rosner B: Epidemiology of otitis media during the first seven years of life in children in Greater Boston: A prospective, cohort study. J Infect Dis (1989) 160(1):83-94.
2. Bennett KE, Haggard MP, Silva PA, Stewart IA: Behavior and developmental effects of otitis media with effusion into the teens. Arch Dis Child (2001) 85(2):91-95.
3. Post JC, Preston RA, Aul JJ, Larkins-Pettigrew M, Rydquist-White J, Anderson KW, Wadowsky RM, Reagan DR, Walker ES, Kingsley LA et al. Molecular analysis of bacterial pathogens in otitis media with effusion. J Am Med Assoc (1995) 273(20):1598-1604.
4. Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Eng J Med (2002) 347(7):465-471.
5. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC: Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveil Summ (2002) 51(6):1-16.
6. Bernstein JM, Faden HS, Ogra PL: Nasopharyngeal colonization by nontypeable Haemophilus influenzae in children: The effect of serum bactericidal antibody. Otolaryngol Head Neck Surg (1991) 105(3):406-410.
7. Bernstein JM: Immunologic reactivity in the middle ear in otitis media with effusion. Otolaryngol Clin North Am (1991) 24(4):845-858.
8. Forsgren A, Akkoyunlu M, Hermansson A, Janson H, Ruan M, Melhus Å, Prellner K: Protection against experimental otitis media (AOM) by vaccination with protein D of Haemophilus influenzae (Hi). ICAAC (1992) 32: Abs 972
9. Brinton CC Jr, Carter MJ, Derber DB, Kar S, Kramarik JA, To AC, Wood SW: Design and development of pilus vaccines for Haemophilus influenzae diseases. Pediatr Infect Dis J (1989) 8(Suppl):54-61.
10. Green BA, Doyle WJ, Cowell JL: Chinchilla model of experimental otitis media for study of nontypable Haemophilus influenzae vaccine efficacy. In: Methods in Enzymology: Bacterial Pathogenesis, Part A. Identification and Regulation of Virulence Factors. Clark VL, Bavoil PM (Eds), Academic Press, New York, NY, USA (1994) 235:59-68.
11. Bakaletz LO, Kennedy BJ, Novotny LA, Duquesne G, Cohen J, Lobet Y: Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect Immun (1999) 67(6):2746-2762.
12. Sabirov A, Kodama S, Hirano T, Suzuki M, Mogi G: Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor α production in the murine model of otitis media. Infect Immun (2001) 69(5):2964-2971.
13. Kurono Y, Suzuki M, Mogi G, Yamamoto M, Fujihashi K, McGhee JR, Kiyono H: Effects of intranasal immunization on protective immunity against otitis media. Int J Pediatr Otorhinolaryngol (1999) 49:S227-S229.
14. Hotomi M, Saito T, Yamanaka N: Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin. Vaccine (1998) 16(20):1950-1956.
15. Hotomi M, Yokoyama M, Kuki K, Togawa A, Yamanaka N: Study on specific mucosal immunity by intranasal immunization of outer membrane protein P6 of Haemophilus influenzae with cholera toxin B subunit. Acta Otolaryngol Suppl (1996) 523:150-152.
16. Green BA, Quinn-Dey T, Zlotnick GW: Biologic activities of antibody to a peptidoglycan-associated lipoprotein of Haemophilus influenzae against multiple clinical isolates of H influenzae type B. Infect Immun (1987) 55(12):2878-2883.
17. Murphy TF, Campagnari AA, Nelson MB, Apicella MA: Somatic antigens of Haemophilus influenzae as vaccine components. Pediatr Infect Dis J (1989) 8(1 Suppl):S66-S68.
18. Green BA, Farley JE, Quinn-Dey T, Deich RA, Zlotnick GW: The e (P4) outer membrane protein of Haemophilus influenzae: Biologic activity of anti-e serum and cloning and sequencing of the structural gene. Infect Immun (1991) 59(9):3191-3198.
19. Akkoyunlu M, Janson H, Ruan M, Forsgren A: Biological activity of serum antibodies to a nonacylated form of lipoprotein D of Haemophilus influenzae. Infect Immun (1996) 64(11):4586-4592.
20. Zagursky RJ, Ooi P, Jones KF, Fiske MJ, Smith RP, Green BA: Identification of a Haemophilus influenzae 5′-nucleotidase protein: Cloning of the nucA gene and immunogenicity and characterization of the NucA protein. Infect Immun (2000) 68(5):2525-2534.
21. DeMaria TF, Murwin DM, Leake ER: Immunization with outer membrane protein P6 from nontypeable Haemophilus influenzae induces bactericidal antibody and affords protection in the chinchilla model of otitis media. Infect Immun (1996) 64(12):5187-5192.
22. Loosmore SM, Yang Y-P, Oomen R, Shortreed JM, Coleman DC, Klein MH: The Haemophilus influenzae HtrA protein is a protective antigen. Infect Immun (1998) 66(3):899-906.
23. Green BA, Vazquez ME, Zlotnick GW, Quigley-Reape G, Swarts JD, Green I, Cowell JL, Bluestone CD, Doyle WJ: Evaluation of mixtures of purified Haemophilus influenzae (Hi) outer membrane proteins in protection against challenge with nontypeable Hi in the chinchilla otitis media model. Infect Immun (1993) 61(5):1950-1957.
24. Akkoyunlu M, Forsgren A: Local and systemic antibody levels against protein D of Haemophilus influenzae following immunization and infection in rats. APMIS (1996) 104(10):709-717.
25. Barenkamp SJ: Immunization with high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae modifies experimental otitis media in chinchillas. Infect Immun (1996) 64(4):1246-1251.
26. Cutter D, Mason KW, Howell AP, Fink DL, Green BA, St. Geme JW 3rd: Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice. J Infect Dis (2002) 186(8):1115-1121. This article demonstrates the effects of intranasal immunization with an adhesin on the protection against colonization with NTHi. This route of immunization should be a key method in future vaccine development for this pathogen.
27. Fink DL, Green BA, St. Geme JW 3rd: The Haemophilus influenzae Hap autotransporter binds to fibronectin, laminin, and collagen IV. Infect Immun (2002) 70(9):4902-4907.
28. St. Geme JW 3rd, De La Morena ML, Falkow S: A Haemophilus influenzae IgA protease-like protein promotes intimate interaction with human epithelial cells. Mol Microbiol (1994) 14(2):217-233.
29. Hotomi M, Yamanaka N, Shimada J, Suzumoto M, Ikeda Y, Sakai A, Arai J, Green B: Intranasal immunization with recombinant outer membrane protein P6 induces specific immune responses against nontypeable Haemophilus influenzae. Int J Pediatr Otorhinolaryngol (2002) 65(2):109-116. This paper reports that intranasal immunization with low levels of cholera toxin and an integral OMP can protect against colonization with NTHi in mice. This is a probable route of immunization for children.
30. Kyd JM, Cripps AW: Potential of a novel protein, OMP26, from nontypeable Haemophilus influenzae to enhance pulmonary clearance in a rat model. Infect Immun (1998) 66(5):2272-2278.
31. Weiser JN, Chong ST, Greenberg D, Fong W: Identification and characterization of a cell envelope protein of Haemophilus influenzae contributing to phase variation in colony opacity and nasopharyngeal colonization. Mol Microbiol (1995) 17(3):555-564.
32. Green BA, Meredith ES, Edwards L, Jones KF: Nontypeable Haemophilus influenzae lipooligosaccharide conjugates as vaccine candidates against NTHi. In: Vaccines 94: Modern Approaches to New Vaccines Including Prevention of AIDS. Ginsberg HS, Brown F, Norrby E (Eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (1994):125-129.
33. Gu X-X, Sun J, Jin S, Barenkamp SJ, Lim DJ, Robbins JB, Battey J: Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas. Infect Immun (1997) 65(11):4488-4493.
34. Gu X-X, Chen J, Barenkamp SJ, Robbins JB, Tsai C-M, Lim DJ, Battey J: Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect Immun (1998) 66(5):1891-1897. This study demonstrated that LOS conjugates can be immunogenic and that antibodies to it are bactericidal.
35. Sun J, Chen J, Cheng Z, Robbins JB, Battey JF, Gu XX: Biological activities of antibodies elicited by lipooligosaccharide based-conjugate vaccines of nontypeable Haemophilus influenzae in an otitis media model. Vaccine (2000) 18(13):1264-1272. This paper describes the activity of LOS conjugate-antibodies against NTHi. Conjugation of polysaccharides has proven to be one of the most effective techniques for immunization and this common antigen may prove to be an efficacious vaccine if common epitopes are immunogenic.
36. Rahman MM, Gu XX, Tsai CM, Kolli VS, Carlson RW: The structural heterogeneity of the lipooligosaccharide (LOS) expressed by pathogenic non-typeable Haemophilus influenzae strain NTHi 9274. Glycobiology (1999) 9(12):1371-1380.
37. Gu X-X, Rudy SF, Chu C, McCullagh L, Kim HN, Chen J, Li J, Robbins JB, Van Waes C, Battey JF: Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae. Vaccine (2003) 21(17-18):2116-2123.
38. Catlin BW: Branhamella catarrhalis: An organism gaining respect as a pathogen. Clin Microbiol Rev (1990) 3(4):293-320. This comprehensive review is a landmark in the M catarrhalis literature. It established once and for all that M catarrhalis is an important pathogen.
39. Hol C, Schalén C, Verduin CM, Van Dijke EEM, Verhoef J, Fleer A, Van Dijk H: Moraxella catarrhalis in acute laryngitis: Infection or colonization? J Infect Dis (1996) 174(3):636-638.
40. Chen D, Barniak V, VanDerMeid KR, McMichael JC: The levels and bactericidal capacity of antibodies directed against the UspA1 and UspA2 outer membrane proteins of Moraxella (Branhamella) catarrhalis in adults and children. Infect Immun (1999) 67(3):1310-1316. This paper reports that the bulk of the bactericidal antibodies resulting from natural exposure of individuals to M catarrhalis are directed toward the UspA proteins.
41. Goldblatt D, Scadding GK, Lund VJ, Wade AM, Turner MW, Pandey JP: Association of Gm allotypes with the antibody response to the outer membrane proteins of a common upper respiratory tract organism, Moraxella catarrhalis. J Immunol (1994) 153(11):5316-5320. This paper established the importance of IgG3 antibodies in protecting individuals from M catarrhalis infections.
42. Carson RT, McDonald DF, Kehoe MA, Calvert JE: Influence of Gm allotype on the IgG subclass response to streptococcal M protein and outer membrane proteins of Moraxella catarrhalis. Immunology (1994) 83(1):107-113.
43. Unhanand M, Maciver I, Ramilo O, Arencibia-Mireles O, Argyle JC, McCracken GH Jr, Hansen EJ: Pulmonary clearance of Moraxella catarrhalis in an animal model. J Infect Dis (1992) 165(4):644-650.
44. Hou Y, Hu W-G, Hirano T, Gu X-X: A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Vaccine (2002) 20(17-18):2375-2381.
45. Chen D, McMichael JC, VanDerMeid KR, Hahn D, Mininni T, Cowell J, Eldridge J: Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect Immun (1996) 64(6):1900-1905.
46. Pearson MM, Lafontaine ER, Wagner NJ, St Geme JW III, Hansen EJ: A hag mutant of Moraxella catarrhalis strain O35E is deficient in hemagglutination, autoagglutination and immunoglobulin D-binding activities. Infect Immun (2002) 70(8):4523-4533. The differences and similarities of the UspA1, UspA2 and Hag proteins are described in this paper.
47. McMichael JC, Fiske MJ, Fredenburg RA, Chakravarti DN, VanDerMeid KR, Barniak V, Caplan J, Bortell E, Baker S, Arumugham R, Chen D: Isolation and characterization of two proteins from Moraxella catarrhalis that bear a common epitope. Infect Immun (1998) 66(9):4374-4381.
48. Aebi C, LaFontaine ER, Cope LD, Latimer JL, Lumbley SL, McCracken GH, Hansen EJ: Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella catarrhalis O35E. Infect Immun (1998) 66(7):3113-3119.
49. Fitzgerald M, Mulcahy R, Murphy S, Keane C, Coakley D, Scott T: A 200 kDa protein is associated with haemagglutinating isolates of Moraxella (Branhamella) catarrhalis. FEMS Immunol Med Microbiol (1997) 18(3):209-216.
50. Cope LD, Lafontaine ER, Slaughter CA, Hasemann CA, Aebi C, Henderson FW, McCracken GH, Hansen EJ: Characterization of the Moraxella catarrhalis uspA1 and uspA2 genes and their encoded products. J Bacteriol (1999) 181(13):4026-4034.
51. Meier PS, Troller R, Grivea IN, Syrogiannopoulos GA, Aebi C: The outer membrane proteins UspA1 and UspA2 of Moraxella catarrhalis are highly conserved in nasopharyngeal isolates from young children. Vaccine (2002) 20(13-14):1754-4760.
52. Lafontaine ER, Wagner NJ, Hansen EJ: Expression of the Moraxella catarrhalis UspA1 protein undergoes phase variation and is regulated at the transcriptional level. J Bacteriol (2001) 183(5):1540-1551.
53. Chen D, McMichael JC, VanDerMeid KR, Masi AW, Bortell E, Caplan JD, Chakravarti D, Barniak VL: Evaluation of a 74-kDa transferrin-binding protein from Moraxella (Branhamella) catarrhalis as a vaccine candidate. Vaccine (1999) 18(1-2):109-118.
54. Helminen ME, Maciver I, Latimer JL, Cope LD, McCracken GH, Hansen EJ: A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect Immun (1993) 61(5):2003-2010.
55. Murphy TF, Brauer AL, Yuskiw N, Hiltke TJ: Antigenic structure of outer membrane protein E of Moraxella catarrhalis and construction and characterization of mutants. Infect Immun (2000) 68(11):6250-6256.
56. Murphy TF, Kyd JM, John A, Kirkham C, Cripps AW: Enhancement of pulmonary clearance of Moraxella (Branhamella) catarrhalis following immunization with outer membrane protein CD in a mouse model. J Infect Dis (1998) 178(6):1667-1675.
57. Reddy MS, Murphy TF, Faden HS, Bernstein JM: Middle ear mucin glycoprotein: Purification and interaction with nontypeable Haemophilus influenzae and Moraxella catarrhalis. Otolaryngol Head Neck Surg (1997) 116(2):175-180.
58. Vaneechoutte M, Verschraegen G, Claeys G, Van Den Abeele AM: Serological typing of Branhamella catarrhalis strains on the basis of lipopolysaccharide antigens. J Clin Microbiol (1990) 28(2):182-187. The basis for the serological typing of LOS of M catarrhalis was established in this paper.
59. Edebrink P, Jansson PE, Rahman MM, Widmalm G, Holme T, Rahman M: Structural studies of the O-antigen oligosaccharides from two strains of Moraxella catarrhalis serotype C. Carbohydr Res (1995) 266(2):237-261.
60. Masoud H, Perry MB, Brisson J-R, Uhrin D, Richards JC: Structural elucidation of the backbone of oligosaccharide from the lipopolysaccharide of Moraxella catarrhalis serotype A. Can J Chem (1994) 72:1466-1477.
61. Hu W-G, Chen J, McMichael JC, Gu X-X: Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis. Infect Immun (2001) 69(3):1358-1363.
62. Jiao X, Hirano T, Hou Y, Gu X-X: Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect Immun (2002) 70(11):5982-5989.
63. Safety evaluation of toxin adjuvants delivered intranasally: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA (2002). http://www.niaid.nih.gov/dmid/enteric/intranasal.htm This is a critical reference for scientists interested in intranasal immunization. The issues regarding the intranasal use of enterotoxin adjuvants are highlighted and the challenges for regulatory approval of this powerful class of mucosal adjuvants are presented.
64. Connaught Laboratories Ltd (Sasaki K, Harkness RE, Loosmoore SM, Klein MH): Nucleic acids encoding high molecular weight major outer membrane protein of Moraxella. US-05808024 (1998).
65. Antex Biologics Inc (Tucker K, Plosila L, Tillman UF): Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof. US-06214981 (2001).